MichaelSiavashKhodadoustMD

PubMed

• Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
  Steven M Horwitz, Ajit J Nirmal, Jahan Rahman, Ran Xu, Esther Drill
  Nature Medicine. 2024-12-01
• Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBAL...
  Swaminathan P Iyer, R Alejandro Sica, P Joy Ho, Anca Prica, Jasmine Zain
  The Lancet. Oncology. 2024-11-28
• ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.
  Amrita Goyal, Daniel O'Leary, Bouthaina Dabaja, Wen-Kai Weng, Jasmine Zain
  Transplantation and Cellular Therapy. 2024-11-01

Journal Articles

• Targeted Killing of TNFR2-Expressing Tumor Cells and Tregs by TNFR2 Antagonistic Antibodies in Advanced Sézary Syndrome  
  D L Faustman, Y H Kim, M Khodadoust, Nature
• Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study  
  Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
• IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 Study  
  Pierluigi Porcu, Basem William, Michael Khodadoust, European Journal of Cancer

Abstracts/Posters

• Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells
  Michael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and N... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018